The central proposition advanced herein is that complex target oriented synthesis, enabled by historic advances in methodology, has enormously expanded the scope of the possible. Accordingly, natural products, a proven long-term source of pharma discovery, re-emerge as potentially valuable elements for synthesis-driven pharma exploitation.
No takes yet. Share an insight, caveat, or question.
Samuel J. Danishefsky (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: